Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Condition(s):Diabetes Mellitus, Type 2; HealthyLast Updated:May 11, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Diabetes Mellitus, Type 2; HealthyLast Updated:May 11, 2017Completed
Condition(s):Renal Insufficiency, ChronicLast Updated:April 18, 2023Recruiting
Condition(s):Heart FailureLast Updated:June 18, 2021Completed
Condition(s):Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3; CKD Stage 4Last Updated:October 23, 2023Not yet recruiting
Condition(s):Diabetes Mellitus, Type 2Last Updated:July 14, 2023Active, not recruiting
Condition(s):Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by AntipsychoticsLast Updated:January 25, 2023Not yet recruiting
Condition(s):Diabetes Mellitus, Type IILast Updated:August 9, 2016Unknown status
Condition(s):Heart FailureLast Updated:November 27, 2020Completed
Condition(s):Diabetes Mellitus, Type 2Last Updated:June 10, 2021Completed
Condition(s):Heart FailureLast Updated:December 8, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.